Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Forest Laboratories announces positive ceftaroline results

Forest Laboratories announces positive ceftaroline results

20th June 2008

Forest Laboratories has announced positive results from two phase III clinical studies of ceftaroline as a treatment for complicated skin and skin structure infections.

Ceftaroline is a broad-spectrum cephalosporin that has activity against gram-negative bactera and gram-positive bacteria including methicillin-resistant Staphylococcus aureus (MRSA).

The company reports that the compound achieved non-inferiority in the Canvas I and Canvas II studies when administered as a monotherapy and compared to vancomycin plus aztreonam, with the drug also generally well tolerated in patients.

Over 30 per cent of the 1,396 patients studied in the trial with a confirmed pathogen were infected with MRSA.

Howard Solomon, chief executive officer of Forest Laboratories, said: “We are extremely pleased with the top-line results demonstrating ceftaroline’s efficacy in treating complicated skin and skin structure infections, particularly in difficult to treat patients.”

He added that there is a need for new broad-spectrum antibiotics to treat the number of infections involving gram-negative pathogens and gram-positive pathogens including MRSA.

In November 2007, a report from research firm Decision Resources revealed that together with Ceftobiprole from Johnson & Johnson and Basilea, ceftaroline is one of the most promising drugs currently in development for the treatment of community-acquired pneumonia.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.